Insight and
Health
Three drugs approved for Alzheimer’s disease have been hailed as a breakthrough in treating the condition – how effective are they, and what risks and side effects do they come with?
By Grace Wade
Illustration of amyloid plaques (orange) among brain cells
Science Photo Library/Alamy
In early July, the US Food and Drug Administration (FDA) approved a treatment called donanemab for people with early-stage Alzheimer’s disease. It is the second drug shown to slow the condition’s progression, and the third FDA-authorised medication that clears the amyloid proteins that accumulate in the brains of people with Alzheimer’s.
The FDA’s approval of three new drugs – donanemab, lecanemab and aducanumab – in just over three years has led some to declare a leap forward in Alzheimer’s disease treatment. Japan, South Korea, China,…
View introductory offers
No commitment, cancel anytime*
Offer ends 2nd of July 2024.
*Cancel anytime within 14 days of payment to receive a refund on
unserved issues.
Inclusive of applicable taxes (VAT)
or
Existing subscribers
Sign in to your account
More from New Scientist
Explore the latest news, articles and features
>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : New Scientist – https://www.newscientist.com/article/2442061-the-truth-about-the-new-class-of-alzheimers-drugs/?utm_campaign=RSS%7CNSNS&utm_source=NSNS&utm_medium=RSS&utm_content=home
